Real-world impact across clinical development

An early-stage oncology biotech needed a regulator-ready Phase 1/2 strategy - without in-house regulatory expertise and without losing weeks to scattered review cycles.

• Faster convergence on Phase 1 endpoints and early activity strategy
• More defensible rationale with fewer fragmented review cycles
• Earlier detection of feasibility and guideline risks before they became amendments

A mid-size pharma sponsor needed to merge two standalone Phase 1 clinical pharmacology studies into one integrated protocol - quickly and without consistency issues.

• One integrated protocol with multiple arms under a unified Schedule of Activities
• First workable merged draft in days instead of weeks
• Stronger regulatory defensibility and smoother Phase III readiness